TALAZOPARIB TOSYLATE

Search structure
Trade Names:
Synonyms:
Status: Approved (2018)
Entry Type: Small molecule
Molecule Category: Salt
UNII: 02WK9U5NZC
Parent Compound: TALAZOPARIB

Structure
InChI Key QUQKKHBYEFLEHK-QNBGGDODSA-N
Smile Cc1ccc(S(=O)(=O)O)cc1.Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1
InChI
InChI=1S/C19H14F2N6O.C7H8O3S/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28;1-6-2-4-7(5-3-6)11(8,9)10/h2-8,15-16,24H,1H3,(H,26,28);2-5H,1H3,(H,8,9,10)/t15-,16-;/m1./s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C26H22F2N6O4S
Molecular Weight 552.56
AlogP 2.63
Hydrogen Bond Acceptor 6.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 2.0
Polar Surface Area 88.49
Molecular species NEUTRAL
Aromatic Rings 4.0
Heavy Atoms 28.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Poly [ADP-ribose] polymerase-1 inhibitor PubMed

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Breast Neoplasms 4 D001943 FDA
Breast Neoplasms 4 D001943 FDA
Breast Neoplasms 4 D001943 ClinicalTrials
Triple Negative Breast Neoplasms 2 D064726 ClinicalTrials
Carcinoma, Non-Small-Cell Lung 2 D002289 ClinicalTrials
Leukemia, Myeloid, Acute 1 D015470 ClinicalTrials
Neoplasms 1 D009369 ClinicalTrials

Related Entries

Scaffolds

Parent

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Blood and lymphatic system disorders
20.83
Investigations
13.89
Eye disorders
12.5
Injury, poisoning and procedural complications
12.5
General disorders and administration site conditions
9.72
Gastrointestinal disorders
8.33
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
8.33
Nervous system disorders
5.56
Skin and subcutaneous tissue disorders
4.17

Cross References

Resources Reference
ChEMBL CHEMBL3137318
FDA SRS 02WK9U5NZC
PubChem 135565654
SureChEMBL SCHEMBL2717160
CONTENTS